Questions? Call 800-624-6242 About | Ordering | New Menu | Items in cart [0] SEARCH

PAPERBACK price:$39.00 add to cart Rights & Permissions Free PDF Access Sign in to download PDF book and chapters Free Resources PDF SUMMARY Display this book on your site! Related Titles Adverse Effects of Vaccines: Evidence and Causality Immunization Safety Review: Thimerosal - Containing Vaccines and Neurodevelopmental Disorders Other Related Titles Immunization Safety Review: Vaccines and Autism (2004) Board on Health Promotion and Disease Prevention (HPDP) Institute of Medicine (IOM) Citation Manager Export the bibliographic data for this book in your chosen format Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Citation Manager . "Appendix C: Thimerosal Content in Licensed Vaccines." Immunization Safety Review: Vaccines and Autism. Washington, DC: The National Academies Press, 2004. Please select a format: Page 183   E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Appendix C Thimerosal Content in Licensed Vaccines (Adapted from FDA, 2003, 2004) Page 183 Front Matter (R1-R14) Executive Summary (1-20) Immunization Safety Review: Vaccines and Autism (21-153) References (154-164) Appendix A: Committee Recommendations and Conclusions from Previous Reports (165-179) Appendix B: Public Meeting Agenda, February 9, 2004 (180-182) Appendix C: Thimerosal Content in Licensed Vaccines (183-186) Appendix D: Chronology of Important Events Regarding Vaccine Safety (187-191) Appendix E: Summary of Public Submissions (192-196) Appendix F: Acronyms (197-200)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 183
Immunization Safety Review: Vaccines and Autism Appendix C Thimerosal Content in Licensed Vaccines (Adapted from FDA, 2003, 2004)

OCR for page 184
Immunization Safety Review: Vaccines and Autism TABLE C-1 Mercury Content from Thimerosal in the Routinely Recommended Pediatric Vaccines1 in the United States, April 2004 Vaccine Brand Name Manufacturer Hg [μg/dose] DTaP (Diphtheria and tetanus toxoids and acellular pertussis) Tripedia Aventis Pasteur, Inc. ≤0.3 Infanrix Glaxo-SmithKline 0 Daptacel Aventis Pasteur, Ltd 0 Td1 (Tetanus and diphtheria toxoids) None Aventis Pasteur, Inc. 25 Decavac Aventis Pasteur, Inc. = 0.3 None Aventis Pasteur, Ltd 0 None Mass Public Health 8.3 DTaP-Hib (Diphtheria and tetanus toxoids with acellular pertussis combined with Haemophilus influenzae type b) TriHIBit2 Aventis Pasteur ≤0.3 Hib (Haemophilus influenzae type b) ActHIB/OmniHib Aventis Pasteur, SA 0 HibTITER (Single dose) Wyeth-Lederle 0 PedvaxHIB liquid Merck 0 Hib/HepB (Haemophilus influenzae type b combined with Hepatitis B ) COMVAX Merck 0 Hep B (Hepatitis B) (pediatric formulation) Engerix B Glaxo-SmithKline <0.5 Recombivax HB Merck 0 Influenza Fluzone3 Aventis Pasteur, Inc. 12.5 Fluzone Aventis Pasteur, Inc. ≤0.5ug/ (Preservative Free)   0.25mL dose Pneumococcal Prevnar (pneumoconjugate) Wyeth 0 IPV (Inactivated polio vaccine) IPOL Aventis Pasteur, SA 0 Poliovax Aventis Pasteur, Ltd. 0 MMR (Measles, mumps, and rubella) MMR-II Merck 0 Varicella Varivax Merck 0 1Licensed for persons 7 years of age and older. 2For use in children 15 to 18 months of age. 3Influenza vaccine is recommended for children 6-23 months of age. MMWR (2004) 52:1-4; MMWR (2004) 53:1-3.

OCR for page 185
Immunization Safety Review: Vaccines and Autism TABLE C-2 Mercury Content from Thimerosal in the Currently Licensed Vaccines That Are Recommended for Some Children in the United States, April 2004 Vaccine Brand Name Manufacturer Hg [μg/dose] DT (Diphtheria and tetanus toxoids) All Products Aventis Pasteur, Inc. (single dose) 0.3   Aventis Pasteur, Inc. (multi-dose) 25   Aventis Pasteur, Ltd* 25 TT (Tetanus Toxoid) All Products Aventis Pasteur, Inc. 25 Pneumococcal Polysaccharide Pneumovax 23 Merck 0 Hepatitis A Havrix Glaxo-SmithKline 0 Vaqta Merck 0 Influenza Fluzone1 Aventis Pasteur, Inc. 25 Fluzone (Preservative free) Aventis Pasteur, Inc. ≤1 μg/0.5 mL dose or ≤0.5 μg/ 0.25 mL dose Fluvirin Evans 25 Fluvirin Evans <1 μg Influenza, Live FluMist MedImmune 0 *Not available in the United States. 1Children under 3 years of age received half of a vaccine dose (0.25 mL or 12.5 μg mercury/dose).

OCR for page 186
Immunization Safety Review: Vaccines and Autism TABLE C-3 Mercury Content from Thimerosal in Other Licensed Vaccines in the United States, April 2004 Vaccine Brand Name Manufacturer Hg [μg/dose] Anthrax BioThrax BioPort Corporation 0 Smallpox Dryvax Wyeth 0 BCG*   Organon Tecknika 0 Mycobax Aventis Pasteur, Ltd 0 Hepatitis A-Hepatitis B Twinrix Glaxo-SmithKline <1 μg Hepatitis B Engerix B (adult formulation) Glaxo-SmithKline < 0.5   Recombivax HB (adult formulation) Merck 25   Recombivax HB (adult formulation) Merck 0 Lyme* LYMErix Glaxo-SmithKline 0 Meningococcal1 Menomune A, C, AC and A/C/Y/W-135 Aventis Pasteur, Inc. (multidose) 25   Single dose 0 Rabies IMOVAX Aventis Pasteur SA 0 Rabavert Chiron Behring 0 Typhoid Fever Typhim Vi Aventis Pasteur SA 0 Vivotif Berna Berna Biotech, Ltd. 0 Yellow Fever YF-VAX Aventis Pasteur, Inc. 0 Japanese Encephalitis Vaccine JE-VAX Aventis Pasteur, Inc. 35 *Not available in the United States. 1Menomune A/C/Y/W-135, a thimerosal-containing vaccine, is not indicated for infants and children younger than 2 years of age except as short-term protection of infants 3 months and older against Group A. (Physician’s Desk Reference, 2001).

Representative terms from entire chapter:

influenzae type